Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD). in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver / Dig Liver Dis. 2024 Sep;56(9):1483-1489. doi: 10.1016/j.dld.2024.01.176. Epub 2024 Jan 30.

2024
AOU Città della Salute di Torino
ASL Torino 3

Tipo pubblicazione

Multicenter Study

Autori/Collaboratori (34)Vedi tutti...

Klersy C
Servizio di Epidemiologia Clinica & Biometria, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
Di Sabatino A
Medicina Generale I, Fondazione IRCCS Policlinico San Matteo e Università di Pavia, 27100 Pavia, Italy. Electronic address: a.disabatino@smatteo.pv.it.
Vecchi M
Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico and Università degli Studi di Milano, 20122 Milan, Italy.

et alii...

Abstract

BACKGROUND: The RIDART I study found a 13.6% prevalence of anemia in Italian patients with inflammatory bowel disease (IBD); most cases were due to iron-deficiency anemia (IDA). AIMS: To evaluate changes in hemoglobin concentration during a 24-week follow-up of anemic patients with IBD. METHODS: Follow-up laboratory and clinical data were obtained from RIDART I study patients with anemia. Factors affecting hemoglobin concentration, the impact of anemia on fatigue and quality of life (QoL), and its relationship with treatment, disease activity and disease complications were investigated. RESULTS: Hemoglobin was 108 g/L at baseline, increased to 121 g/L at follow-up week 12 (p < 0.001) and then stabilized until week 24, but most patients remained anemic, with IDA, throughout the study. Hemoglobin improvement was greater in patients receiving either oral or parenteral iron supplementation. Following hemoglobin normalization, anemia relapse rate during follow-up was 30%. Oral iron did not cause disease reactivation. Lower follow-up hemoglobin was associated with a higher probability of having active disease, clinical complications, increased fatigue and reduced QoL. CONCLUSIONS: In anemic patients with IBD, anemia represents a long-lasting problem, in most cases persisting for up to 24 weeks, with high relapse rate and a negative impact on fatigue and QoL.

Accesso banca dati bibliografica

PMID : 38296690

DOI : 10.1016/j.dld.2024.01.176

Keywords

Inflammatory bowel disease; Young Adult; Anemia therapy; Anemia/etiology; Recurrence; Fatigue/etiology; Iron/administration & dosage/therapeutic use; Middle Aged; Anemia, Iron-Deficiency/etiology/drug therapy; Inflammatory Bowel Diseases/complications; Follow-Up Studies; Adult; Hemoglobins/analysis; Quality of Life; Italy/epidemiology; Female; Male; Humans; Iron-deficiency anemia; Vitamin-deficiency anemia;